Trixeo Aerosphere® receives positive EU CHMP opinion as first inhaled medicine using next-generation propellant with near-zero Global Warming Potential.

Aerosphere®(budesonide/glycopyrronium/formoterol fumarate or BGF), already licensed for the treatment of chronic obstructive pulmonary disease (COPD) in adults, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, endorsing it for use in the European Union (EU) with an innovative, next-generation propellant with near-zero Global Warming Potential (GWP). Approximately 36 million people in Europe are living with COPD and it is the leading cause of death in the EU and the 3th leading cause globally (excluding COVID)...